The National Institute for Health and Care Excellence (NICE) has launched a second consultation on the potential of offering genetic testing shortly after having a stroke to identify the best treatment option.
'Recommending a genetic test that can offer personalised care to thousands of people who have a stroke each year will be a step forward in ensuring people receive the best possible treatment,' explained Professor Jonathan Benger, chief medical officer at NICE.
Evidence has suggested that people who carry certain CYP2C19 genetic variants have an increased risk of another stroke when taking the stroke-prevention treatment clopidogrel.
People identified to have a CYP2C19 variant would be offered alternative stroke-prevention treatments.
Read more here.
